navamepent   

GtoPdb Ligand ID: 9463

Synonyms: RX-10045
Compound class: Synthetic organic
Comment: Navamepent (RX-10045) is a stable resolvin E1 analogue, that is being investigated for clinical efficacy in occular inflammation [3]. Chemically this is an isopropyl ester prodrug of resolvin E1 (an agonist of the chemerin receptor). The chemical structure is claimed in patent US20140275247A1 (as Example 1001) [2]. Findings from animal studies are reported in [1] and [4].
2D Structure
Click here for structure editor
Physico-chemical Properties
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 66.76
Molecular weight 304.17
XLogP 2.51
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Canonical SMILES C#CCC(C=CC=CC#CC(CCCC(=O)OC(C)C)O)O
Isomeric SMILES C#CC[C@H](/C=C/C=C/C#C[C@H](CCCC(=O)OC(C)C)O)O
InChI InChI=1S/C18H24O4/c1-4-10-16(19)11-7-5-6-8-12-17(20)13-9-14-18(21)22-15(2)3/h1,5-7,11,15-17,19-20H,9-10,13-14H2,2-3H3/b6-5+,11-7+/t16-,17-/m1/s1
InChI Key ZVOCIIHCJJEFRQ-BHXBHYJPSA-N
Immunopharmacology Comments
A metabolically stable resolvin E1 analogue, that has completed Phase 2 clinical evaluation in several occular inflammation conditions.
Immunopharmacology Disease
Disease X-Refs Comment References
Allergic conjunctivitis Disease Ontology: DOID:11204
Phase 2 clinical trial NCT01639846 has been completed.
keratoconjunctivitis sicca Disease Ontology: DOID:12895
Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.